Health-related quality of life study of tislelizumab versus single-agent chemotherapy in second-line treatment for advanced urothelial cancer in real-world clinical practice
BIAN xiaojie , SHEN yijun , ZHU yiping, MA chunguang, GU chengyuan, YE dingwei
1.Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
BIAN xiaojie , SHEN yijun , ZHU yiping, MA chunguang, GU chengyuan, YE dingwei. Health-related quality of life study of tislelizumab versus single-agent chemotherapy in second-line treatment for advanced urothelial cancer in real-world clinical practice[J]. China Oncology, 2020, 30(10): 798-805.